H2 Receptor Antagonists and Osteoporosis: Not Recommended
H2 receptor antagonists (H2RAs) should be avoided in older adults with osteoporosis, as they are associated with increased fracture risk and lower bone mineral density, particularly in those with inadequate calcium intake. 1, 2, 3
Common H2 Receptor Antagonists
The H2RAs that have been studied in relation to osteoporosis include:
- Ranitidine (historically used at 300 mg daily) 4
- Cimetidine
- Famotidine
- Nizatidine
These medications are frequently prescribed for gastroesophageal reflux disease and peptic ulcer disease, often in combination with other anti-peptic agents. 1
Evidence Against H2RA Use in Osteoporosis
Fracture Risk
Combined use of H2RAs with proton pump inhibitors (PPIs) significantly increases osteoporotic fracture risk (HR 1.58) compared to PPI alone, with triple therapy including mucoprotective agents showing even higher risk (HR 1.71). 1
H2RA use alone is associated with increased fracture risk (HR 1.44) in population-based studies. 1
When combined with bisphosphonates, H2RAs increase hip fracture risk (ARR 1.24) and any fracture risk (ARR 1.08), negating some protective effects of osteoporosis treatment. 2
Bone Mineral Density Effects
H2RA users demonstrate lower adjusted femoral neck bone mineral density (0.69 g/cm²) compared to nonusers (0.72 g/cm²), particularly when daily calcium intake is below 800 mg. 5
Men using H2RAs show lower cross-sectional bone mass on multivariate analysis. 3
Clinical Implications for Osteoporosis Management
Primary Treatment Recommendations
The evidence-based first-line treatments for osteoporosis in older adults remain:
- Oral bisphosphonates (alendronate or risedronate) for postmenopausal women and men with osteoporosis 6, 7
- Denosumab or zoledronic acid as second-line options 6, 7
- Sequential therapy with bone-forming agents followed by anti-resorptives for very high fracture risk 7
Avoiding H2RA-Related Complications
The 2019 American Geriatrics Society Beers Criteria downgraded the evidence level for H2RAs in delirium from moderate to low, and removed H2RAs from the list of drugs to avoid in dementia, though concerns about fracture risk remain. 8
If acid suppression is necessary in osteoporotic patients, consider mucoprotective agents combined with PPIs rather than adding H2RAs, as this combination does not show increased fracture risk compared to PPI alone. 1
Mechanism of Harm
H2RAs may impair calcium absorption by reducing gastric acid secretion, which is essential for calcium ionization and absorption in the proximal small intestine. 5
The effect is dose-dependent and particularly pronounced in patients with inadequate calcium supplementation (less than 800 mg daily). 5
Common Clinical Pitfall
Clinicians frequently co-prescribe H2RAs with bisphosphonates to manage upper gastrointestinal symptoms, with 7.5% of bisphosphonate users receiving H2RAs in the 6 months before therapy initiation. 2 This practice should be avoided, as it increases fracture risk and may compromise bisphosphonate efficacy.